Status:
COMPLETED
Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Diffuse Large B-cell Lymphoma
Mantle Cell Lymphoma
Eligibility:
All Genders
18-75 years
Brief Summary
This study is designed to monitor all patients exposed to CD19 CAR-T expressing IL7 and CCL19 for 5 years following infusion, to assess their long-term efficacy, including the CAR-vector persistence, ...
Detailed Description
Patients are enrolled following completion from the early clinical study of CD19-7X19 CAR-T treatment ( NCT03258047) and will be followed for 5 years post treatment from the last treatment. They will ...
Eligibility Criteria
Inclusion
- All patients who have received the CD19-IL7/CCL19 CAR-T therapy in the earlier enrolled clinical trail and met including and excluding criteria criteria (NCT0325847) Patients who have provided informed consent for the long term follow up study prior to their study participation .
Exclusion
- There are no specific exclusion criteria for this study.
Key Trial Info
Start Date :
September 22 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2024
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04833504
Start Date
September 22 2018
End Date
October 1 2024
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hui Liu
Hangzhou, State..., China, 310000